Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0156 in Advanced Malignancies
NCT02588105Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2015
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of AZD0156 in solid tumor (advanced stage), sponsored by AstraZeneca. Primary endpoint: Number of patients experiencing adverse events at 6 months. Started Nov 2015; status: completed.
02
Drugs
AZD0156
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02588105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02588105.